Longitudinal evaluation of CA-125 velocity and prediction of ovarian cancer

被引:15
|
作者
Xu, Jian-Lun [1 ]
Commins, John [2 ]
Partridge, Edward [3 ]
Riley, Thomas L. [2 ]
Prorok, Philip C. [1 ]
Johnson, Christine C. [4 ]
Buys, Saundra S. [5 ]
机构
[1] NCI, Biometry Res Grp, Bethesda, MD 20892 USA
[2] Informat Management Serv Inc, Rockville, MD USA
[3] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA
[4] Henry Ford Hlth Syst, Detroit, MI USA
[5] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
关键词
CA-125; Ovarian cancer; Screening; Velocity; LOGISTIC-REGRESSION ANALYSIS; PROGNOSTIC MODELS; SERUM CA-125; PROSTATE; LUNG;
D O I
10.1016/j.ygyno.2011.12.440
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. To determine whether CA-125 velocity is a statistically significant predictor of ovarian cancer and develop a classification rule to screen for ovarian cancer. Methods. In the ovarian component of the PLCO cancer screening trial, 28,038 women aged 55-74 had at least two CA-125 screening tests. Ovarian cancer was diagnosed in 72 (0.26%) women. A multiple logistic regression model was developed to evaluate CA-125 velocity and other related covariates as predictors of ovarian cancer. Predictive accuracy was assessed by the concordance index and measures of discrimination and calibration while the fit of the model was assessed by the Hosmer and Lemeshow's goodness-of-fit chi(2) test. Results. CA-125 velocity decreased as the number of CA-125 measurements increased but was unaffected by age at baseline screen and family history of ovarian cancer. The average velocity (19.749 U/ml per month) of the cancer group was more than 500 times the average velocity (0.035 U/ml per month) of the non-cancer group. Conclusion. Among six covariates used in the model, CA-125 velocity and time intervals between baseline and second to last screening test and between last two screening tests were statistically significant predictors of ovarian cancer. The chance of having ovarian cancer increased as velocity increased, and the chance decreased when the time intervals between baseline and the second to last screening test and between last two screening tests of an individual increased. Published by Elsevier Inc.
引用
收藏
页码:70 / 74
页数:5
相关论文
共 50 条
  • [21] Novel fluoroimmunoassay for ovarian cancer biomarker CA-125
    Sok, Davin
    Clarizia, Lisa-Jo A.
    Farris, Leslie R.
    McDonald, Melisenda J.
    ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2009, 393 (05) : 1521 - 1523
  • [22] CA-125 - MARKER OF OVARIAN-CANCER OR ASCITES
    BERGMANN, JF
    BIDART, JM
    GEORGE, M
    BEAUGRAND, M
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 1987, 11 (2BIS): : A215 - A215
  • [23] CA-125: An evolving role in the management of ovarian cancer
    Markman, M
    JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (05) : 1411 - 1412
  • [24] SCREENING FOR OVARIAN-CANCER BY CA-125 MEASUREMENT
    CRUICKSHANK, DJ
    LANCET, 1988, 1 (8584): : 540 - 541
  • [25] MARKERS SUPPLEMENTING CA-125 IN OVARIAN-CANCER
    STENMAN, UH
    ALFTHAN, H
    VARTIAINEN, J
    LEHTOVIRTA, P
    ANNALS OF MEDICINE, 1995, 27 (01) : 115 - 120
  • [26] CA-125 and Ceruloplasmin Levels in Ovarian Cancer Patients
    Hegde, Mangala
    Chianeh, Yousef Rezaei
    Shetty, Jeevan
    Fernandes, Donald J.
    Rao, Pragna
    CUKUROVA MEDICAL JOURNAL, 2015, 40 (03): : 510 - 516
  • [27] PREDICTION OF THE PRESENCE OF OVARIAN-CANCER BY AN IMMUNOCHEMICAL PANEL - CA-125, COPPER AND ZINC
    LISCHINSKY, S
    FRIEDMAN, M
    GAL, D
    ZINDER, O
    JOURNAL OF CLINICAL CHEMISTRY AND CLINICAL BIOCHEMISTRY, 1988, 26 (06): : 376 - 376
  • [28] Evaluation of HE4 and TTR for diagnosis of ovarian cancer: Comparison with CA-125
    Zheng, Xin
    Chen, Shulin
    Li, Linfang
    Liu, Xiaohua
    Liu, Xiaomin
    Dai, Shuqin
    Zhang, Peng
    Lu, Huaiwu
    Lin, Zhongqiu
    Yu, Yuefei
    Li, Guorong
    JOURNAL OF GYNECOLOGY OBSTETRICS AND HUMAN REPRODUCTION, 2018, 47 (06) : 227 - 230
  • [29] Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer
    Rustin, GJS
    Bast, RC
    Kelloff, GJ
    Barrett, JC
    Carter, SK
    Nisen, PD
    Sigman, CC
    Parkinson, DR
    Ruddon, RW
    CLINICAL CANCER RESEARCH, 2004, 10 (11) : 3919 - 3926
  • [30] PROSPECTIVE EVALUATION OF SERUM CA-125 LEVELS FOR EARLY DETECTION OF OVARIAN-CANCER
    EINHORN, N
    SJOVALL, K
    KNAPP, RC
    HALL, P
    SCULLY, RE
    BAST, RC
    ZURAWSKI, VR
    OBSTETRICS AND GYNECOLOGY, 1992, 80 (01): : 14 - 18